Copenhagen – it’s the end of Day 2 of the European Society for Medical Oncology (ESMO), which this year had a record-breaking 20,239 attendees.
Three of the presentations in today’s plenary Presidential Symposium were simultaneously published in The New England Journal of Medicine – I haven’t seen that happen before.
All three were also featured in this morning’s media briefing in Copenhagen.
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer (NEJM link)
- Prolonged Survival in Stage III Melanoma with ipilimumab Adjuvant Therapy (NEJM link)
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer (NEJM link)
In today’s daily digest there’s top-line commentary and insights from some of the sessions we attended. In a separate post, we have already discussed the niraparib data.